Physician profile
Paige E Pepaj
NPI 1689326720
$4,244.15
in general payments reported to CMS, 2019-2025
18 companies · $1,649 in 2025
The $1,649 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $303 · 2023: $743 · 2024: $1,549 · 2025: $1,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,667 · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,666.87 |
| Education | $273.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $896.95 | 2022-2025 | Remodulin, Orenitram, Remodulin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $833.96 | 2022-2025 | Ofev, Jascayd |
| Astellas Pharma US INC | $723.71 | 2022-2025 | Cresemba |
| Ani Pharmaceuticals, INC. | $447.16 | 2023-2025 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $297.16 | 2023-2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $198.76 | 2023-2025 | Winrevair, Recarbrio, Prevymis |
| Mallinckrodt Hospital Products INC. | $143.99 | 2024-2025 | Acthar, Terlivaz |
| Shionogi INC | $129.88 | 2023-2025 | Fetroja |
| Takeda Pharmaceuticals U.S.A., INC. | $106.14 | 2023-2024 | Livtencity |
| Melinta Therapeutics, LLC | $98.12 | 2023-2024 | Vabomere, Rezzayo, Kimyrsa |
| Vertex Pharmaceuticals Incorporated | $96.79 | 2023-2025 | Trikafta |
| Mylan Specialty L.P. | $62.54 | 2022-2024 | Tobi Podhaler |
| Invivyd INC | $48.19 | 2025 | Pemgarda |
| Vapotherm INC | $46.82 | 2023 | Vapotherm |
| Atricure, INC. | $44.40 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veloxis Pharmaceuticals, INC. | $35.03 | 2024 | Envarsus |
| Csl Behring | $20.63 | 2024 | Kcentra |
| Baxter Healthcare | $13.92 | 2023 | Hillrom - Life 2000 Ventilation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paige Pepaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.